Labcorp Holdings Inc. disclosed that the Centers for Medicare & Medicaid Services released preliminary Clinical Laboratory Fee Schedule payment rates for 2027 through 2029 under PAMA. The company stated these rates are based on unrepresentative data and impose steep annual cuts threatening patient access, prompting continued support for the RESULTS Act. Labcorp reaffirmed its long-term outlook announced September 10, 2026: compound annual revenue growth of 5% to 8%, adjusted operating margin expansion of 75 to 150 basis points by end-2029, and adjusted EPS growth of 8.5% to 11.5%. The company expects to assess the CMS rates' impact on 2027 guidance in February 2027. Labcorp Holdings Inc. operates in the diagnostic laboratory services industry.
